홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
SPRO
#3194
Spero Therapeutics, Inc. Common Stock
2.1
7
-0.46%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-0.46%
월간 변동
-8.05%
6달 변화
+10.15%
년간 변동율
+178.21%
이전 종가
2.1
8
Open
2.1
7
Bid
Ask
Low
2.1
7
High
2.1
7
양
8
마켓
주식
헬스케어
SPRO
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
29.5 M
32.76 M
52.57 M
53.87 M
55.9 M
—
Valuation ratios
Enterprise value
486.88 M
411.84 M
-17.63 M
5.55 M
4.69 M
185.36 M
Price to earnings ratio
—
—
-1.41
3.53
-0.81
-6.71
Price to sales ratio
—
—
1.22
0.78
1.16
7.85
Price to cash flow ratio
—
—
-8.46
-2.44
-2.37
6.05
Price to book ratio
—
—
0.86
0.75
1.21
3.01
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.51
0.52
0.37
0.13
0.62
0.53
Return on equity %
0.59
1.02
0.61
0.21
1.49
1.19
Return on invested capital %
1 225.35
1 563.16
698.97
122.86
412.12
—
Gross margin %
100
100
100
100
100
400
Operating margin %
847.94
481.87
78.86
20.7
152.91
557.88
EBITDA margin %
—
—
—
—
—
—
Net margin %
839.23
491.89
86.74
21.98
142.91
522.53
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
9.7
8.46
5.25
3.53
2.19
12.56
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.07
0.11
0.36
0.68
0.33
0.48
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0
0
0
0
0
—
Long term debt to total equity ratio
0
0
0
0
0
—
Per share metrics
Operating cash flow per share
—
—
0.21
0.62
0.43
-1.13
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
2.9
1.44
0.98
3.28
Net current asset value per share
—
—
3.02
2.48
1.99
5.32
Tangible book value per share
—
—
2.02
2.02
0.85
2.52
Working capital per share
—
—
2.45
1.77
1.08
3.38
Book value per share
—
—
2.02
2.02
0.85
2.52
뉴스
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO)
Keutzer, Spero Therapeutics COO, 4.4만 달러 상당 주식 매도
Keutzer, Spero Therapeutics COO, sells $44k in shares
스페로 테라퓨틱스 CEO, 2억 748만원 상당 주식 매도
Spero Therapeutics CEO sells $207k in stock
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook
Spero Therapeutics announces board resignation and SEC investigation closure
GSK files NDA resubmission for Spero’s tebipenem HBr antibiotic
Spero Therapeutics Q3 실적 예상치를 넘어, 수익 에상치보다 저조
Spero Therapeutics earnings beat by $0.26, revenue fell short of estimates
스페로 테라퓨틱스 CEO, Rajavelu, 9만 5천 달러 상당 주식 매도
Spero therapeutics CEO Rajavelu sells $95k in stock